Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
The Journal of Headache and Pain|July 11, 2021
Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS studyMessoud Ashina, Joshua M Cohen, Maja Galic, et al.
JPRAS Open|March 10, 2025
Rare presentation and resection of giant cell tumor invading the middle ear and skull base: A case reportJoshua M Cohen, Geena Jung, Hailey Reisert, et al.
Headache|November 25, 2022
Burden of migraine in Brazil: A cross-sectional real-world studyMarcio Nattan Portes Souza, Joshua M Cohen, Tony Piha, et al.
The Journal of Headache and Pain|January 8, 2021
Immunogenicity of biologic therapies for migraine: a review of current evidenceJoshua M Cohen, Xiaoping Ning, Yoel Kessler, et al.
Headache|November 12, 2020
Reversion From Chronic Migraine to Episodic Migraine in Patients Treated With Fremanezumab: Post Hoc Analysis From HALO CM StudyRichard B Lipton, Joshua M Cohen, Kristen Bibeau, et al.
The Journal of Headache and Pain|December 21, 2021
Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United StatesPeter McAllister, Lois Lamerato, Lynda J Krasenbaum, et al.
Advances in Therapy|November 9, 2022
Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting SystemStephen D Silberstein, Shoshana Reshef, Joshua M Cohen, et al.
Plastic and Reconstructive Surgery|January 3, 2019
Survival after Digit Replantation and Revascularization Is Not Affected by the Use of Interpositional Grafts during Arterial RepairZ-Hye Lee, Christopher S Klifto, Michael T Milone, et al.
Cephalalgia : an International Journal of Headache|March 25, 2022
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studiesHans Christoph Diener, Peter McAllister, Tim P Jürgens, et al.
Headache|April 13, 2019
Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical TrialsStephen D Silberstein, Peter McAllister, Xiaoping Ning, et al.
Pageof 9